Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting (COSAVEGUL-1)
|Triple Vessel Disease Unstable Angina Stable Angina Myocardial Infarction||Procedure: Upper leg vein harvesting Procedure: Lower leg vein harvesting|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Comparison of Histologic and Immunohistochemical Characteristics Between the Upper and Lower Leg Saphenous Veins Used for Coronary Artery Bypass Grafting|
- Endothelial preservation of saphenous vein graft [ Time Frame: 1 year ]Participants will be followed for the duration of hospital stay, an expected average of 1 week.
|Study Start Date:||October 2013|
|Study Completion Date:||June 2016|
|Primary Completion Date:||April 2015 (Final data collection date for primary outcome measure)|
Active Comparator: Upper leg vein
Upper leg vein harvesting
Procedure: Upper leg vein harvesting
Patients whose saphenous veins are harvested from upper legs.
Active Comparator: Lower leg vein
Lower leg vein harvesting
Procedure: Lower leg vein harvesting
Patients whose saphenous veins are harvested from lower legs.
- Patients aged from 40 to 75 years with triple vessel disease
- Patients who are eligible for the use of left internal thoracic artery as an in situ primary conduit
- Operation plan: saphenous vein graft will be Y-anastomosed to left internal thoracic artery.
- Patients whose saphenous vein grafts can be harvested from both upper legs and lower legs
- Patients who are eligible for off-pump coronary artery bypass grafting
- Patients who agreed with the participation in the research based on thorough explanation.
Patients will be randomly assigned to upper leg vein (ULV) group and lower leg vein (LLV) group immediately after anesthetic induction.
Pieces of residual saphenous vein graft will be sent for histologic and immunohistochemical examination for the evaluation of endothelial cell preservation and the expression of matrix proteins.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01974492
|Korea, Republic of|
|Seoul National University Hospital|
|Seoul, Korea, Republic of, 110-744|
|Principal Investigator:||Ki-Bong Kim, M.D., Ph.D.||Seoul National University Hospital|